Clinical Trials

Overview

About this study

The purpose of this study is to determine the incidence of postoperative residual weakness (a train-of-four ratio < 0.9) in patients getting ‘fast track anesthesia’ following liver transplantation.  Our clinical practice routinely utilizes sugammadex in this patient population and we have anecdotally observed excellent outcomes. We hypothesize that the incidence of postoperative residual weakness with sugammadex and quantitative monitoring is low (<5%) and that patients receiving fast track anesthesia have shorter hospital length of stays than the national average (12).  Additionally, postoperative pulmonary complications (PPC) can occur from residual weakness.  We will utilize previous definitions of PPCs  (13).  Specifically, postoperative pneumonia within 30 days or respiratory failure that requires unplanned non-invasive mechanical ventilation (such as bilevel positive airway pressure ventilation) or need for reintubation due to respiratory distress will be documented.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Participating Mayo Clinic locations

More information